Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 6/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27377417 | 0.92 | OPRM1 (0.51) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL23274961 | 0.90 | CTSL (0.48) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL1551563 | 0.80 | OPRM1 (0.55) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL27377408 | 0.75 | OPRM1 (0.49) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL28069675 | 0.72 | CTSL (0.44) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL27035112 | 0.72 | OPRM1 (0.45) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL5402661 | 0.72 | OPRM1 (0.62) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL31388936 | 0.71 | CTSL (0.44) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL420296 | 0.71 | OPRM1 (0.53) | OPRM1OPRL1CTSLCTSBCTSK | |
| SCHEMBL28231821 | 0.71 | CTSL (0.45) | OPRM1OPRL1CTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025129104-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SIONNA THERAPEUTICS INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2024-01-04 | — | — | US | disclosed |
| EP-4058439-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003659-A | 5-membered heteroaryl amino sulfonamides for the treatment of conditions mediated by a deficiency in CFTR activity | 健赞公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021097057-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002374-A1 | 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | OPRM1 4379/4885OPRL1 2919/4885CTSL 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.